David Feltquate Named CMO of iTeos Therapeutics

David Feltquate, M.D., Ph.D., has joined iTeos Therapeutics as Chief Medical Officer. Overseeing the company's clinical development and regulatory strategy will be Dr. Feltquate. With the goal of becoming a preeminent oncology enterprise, iTeos is thrilled to have Dr. Feltquate as its Chief Medical Officer. With almost two decades of expertise, Dr. Feltquate has worked in the fields of translational medicine, immuno-oncology clinical development, and diagnostic assay innovation.

Previously, he was Head of Oncology Early Clinical Development and Development Leader for Ipilimumab / Nivolumab Life Cycle Management at Bristol Myers Squibb, Novartis, and Palleon Pharmaceuticals. Dr. Feltquate graduated with honours from the University of Massachusetts Medical School with an M.D./Ph.D. in Immunology and the Massachusetts Institute of Technology with a B.S. in Biology. He finished his studies in medical oncology at Memorial Sloan Kettering Cancer Centre and general medicine at Dartmouth Hitchcock Medical Centre. It is with great pleasure that Dr. Feltquate joins iTeos at this moment, as the firm is expanding its TIGIT franchise and is intent on creating a rich pipeline of new targets for underprivileged patients.

 He thinks working for a firm that is leading the way in creating cutting-edge oncology pipeline, ingrained in a scientifically disciplined, data-driven approach, represents an incredible opportunity to bring novel and potentially transformative therapies to patients.